Press Releases

Azooka Labs, a leading safe fluorophore company with specialization in Molecular Biology products, reveals its first range of novel COVID-19 diagnostics products. RNA Wrapr is a molecular transport medium for COVID-19 sample collection, developed as part of the COVID-19 response team from Indian Institute of Science. RNA Wrapr inactivates the virus immediately only preserving DNA/RNA content required for RT-PCR tests. The sample tubes can be stored up to 7 days in Room Temperature a

Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s lead compound, CPI-613® (devimistat), for the treatment of acute myeloid leukemia (AML). “Receiving Fast Track designation, especially during a pandemic that has created significant challenges for many trials across the globe, is a testament to the ded

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Overland Pharmaceuticals (“Overland”), a premier biopharmaceutical company backed by Hillhouse Capital, today announced the formation of Allogene Overland Biopharm (Allogene Overland). The joint venture will focus on the development, manufacturing and commercialization of AlloCAR T therapies for patients in greater China, T

Pepscope is a Dutch biotechnology company offering innovative endogenous protein kinase activity profiling technologies. Today, Pepscope announces a 4.3-million-euro funding round, led by KIKK Capital, together with Oost NL and the Netherlands Enterprise Agency to further develop and commercialize her lead product QuantaKinome™. QuantaKinome™ is the first technology to provide direct insights into the activities of hundreds of protein kinases simultaneously inside the ce

Avelas Biosciences, Inc., pioneering the field of intraoperative fluorescent cancer imaging,  announced that the company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for pegloprastide (AVB-620) for the intraoperative detection and visualization of positive margins during breast cancer surgery. Pegloprastide is designed to deliver a fluorescent marker to cancer cells to aid surgeons in identifying positive margins in real time during surge

Relay Therapeutics, Inc , a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced it has entered into a worldwide license and collaboration agreement with Genentech, a member of the Roche Group, for the development and commercialization of RLY-1971, a potent inhibitor of SHP2. Under the collaboration, Genentech will assume development of RLY-1971 with the potential to expand into multiple comb

Lexicon Pharmaceuticals, Inc., announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain. “The FDA’s Fast Track designation of LX9211 reflects the serious unmet medical need of people suffering from diabetic peripheral neuropathic pain,” said Praveen Tyle, Ph.D., executive vice president of research and development. “We look forward to working cl

Puma Biotechnology, Inc., a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial were presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. The presentation entitled, “Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial,&rdquo

HALIX B.V. signed an agreement with AstraZeneca AB for large-scale commercial drug substance manufacture of AZD1222, the adenovirus vector-based COVID-19 vaccine. Under the agreement, HALIX will provide commercial manufacturing of drug substance at its state-of-the-art cGMP facility at the Leiden Bio Science Park in the Netherlands. To meet the increased demand, HALIX expands with two additional viral vector production lines. With this agreement, HALIX continues its key ro

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced publication of the results from a 52-subject human clinical trial with the BD Libertas™ Wearable Injector. The subcutaneous drug delivery system, currently in final phases of development, is designed as ready to use and to deliver drugs such as biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations. This research to evaluate the performance of the 5 mL BD Liber